Molecular aspects of atherogenesis: New insights and unsolved questions

Journal of Biomedical Science

Volumn 12, Issue 6, 2005, Pages 839-853

  Puddu, Giovanni Maria ^a   Cravero, Eleonora ^a   Arnone, Giorgia ^a   Muscari, Antonio ^a   Puddu, Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherogenesis; Caveolin; G proteins; Lipoproteins; Oxidant stress; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; CAVEOLIN; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CYTOKINE; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR STIMULATING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; THROMBOPLASTIN; UNINDEXED DRUG;

ARTERY INTIMA; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CAVEOLA; DNA MODIFICATION; DRUG EFFICACY; ENDOTHELIUM CELL; GENE INTERACTION; GENETIC PREDISPOSITION; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; MITOCHONDRION; MOLECULAR DYNAMICS; MONONUCLEAR CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOGENESIS; THROMBUS; VASCULAR DISEASE;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CELL ADHESION; CYTOKINES; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; INSULIN; LEUKOCYTES, MONONUCLEAR; LIPIDS; MITOCHONDRIA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXYGEN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; THROMBOPLASTIN;

THROMBUS;

EID: 30544453439     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-005-9024-z     Document Type: Review

References (180)

1. Goldstein J.L. and Brown M.S., LDL receptor locus and the genetics of familial hypercholesterolemia. Ann. Rev. Genet. 13: 259-289, 1979.
2. Jukema J.W., van Boven A.J., Groenemeijer B., Zwinderman A.H., Reiber J.H., Bruschke A.V., Henneman J.A., Molhoek G.P., Bruin T., Jansen H., Gagne E., Hayden M.R. and Kastelein J.J., The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation 94: 193-1918, 1996.
3. Mailly F., Tugrul Y., Reymer P.W., Bruin T., Seed M., Groenemeyer B.F., Asplund-Carlson A., Vallance D., Winder A.F. and Miller G.J., A common variant in the gene for lipoprotein lipase (Asp9 → Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 15: 468-478, 1995.
4. Pimstone S.N., Gagne S.E., Gagne C., Lupien P.J., Gaudet D., Williams R.R., Kotze M., Reymer P.W., Defesche J.C. and Kastelein J.J., Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1704-1712, 1995.
5. Dzau V.J., Gibbons G.H., Cooke J.P. and Omoigui N., Vascular biology and medicine in the 1990s. scope, concepts, potentials and perspectives. Circulation 87: 705-719, 1993.
6. van den Ende A., van der Hoek Y.Y., Kastelein J.J., Koschinsky M.L., Labeur C. and Rosseneu M., Lipoprotein [a]. Adv. Clin. Chem. 32: 73-134, 1996.
7. Ribichini F., Steffenino G., Dellavalle A., Matullo G., Colajanni E., Camilla T., Vado A., Benetton G., Uslenghi E. and Piazza A., Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. A major risk factor and a marker of risk for coronary stent restenosis. Circulation 97: 147-154, 1998.
8. Fross P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A. and van den Heuvel L.P., A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10: 111-113, 1995.
9. Kluijtmans L.A., Kastelein J.J., Lindemans J., Boers G.H., Heil S.G., Bruschke A.V., Jukema J.W., van den Heuvel L.P., Trijbels F.J., Boerma G.J., Verheugt F.W., Willelms F. and Blom H.J., Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 96: 2573-2577, 1997.
10. Lusis A.J., Atherosclerosis. Nature 407: 233-241, 2000.
11. Doevendans P.A., Jukema W., Spiering W., Defesche J.C. and Kastelein J.J.P., Molecular genetics and gene expression in atherosclerosis. Int. J. Cardiol. 80: 161-172, 2001.
12. Puddu P., Cravero E., Puddu G.M. and Muscari A., Genes and atherosclerosis: at the origin of the predisposition. Int. J. Clin. Pract. 59: 462-472, 2005.
13. Puddu P., Puddu G.M. and Muscari A., Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression? Int. J. Cardiol. 90: 133-140, 2003.
14. Li A.C. and Glass C.K., PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45: 2161-2173, 2004.
15. Marx N., Duez H., Fruchart J.C. and Staels B., Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 14(94) 1168-1178, 2004.
16. Neve B.P., Fruchart J.C. and Staels B., Role of peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 60: 1245-1250, 2000.
17. Duez H., Fruchart J.C. and Staels B., PPAR in inflammation, atherosclerosis and thrombosis. J. Cardiovasc. Risk 8: 187-194, 2001.
18. Elangbam C.S., Tyler R.D. and Lightfoot R.M., Peroxisome proliferator-activated receptors in atherosclerosis and inflammation-an update. Toxicol. Pathol. 29: 224-231, 2001.
19. van Raalte D.H., Li M., Pritchard P.H. and Wasan K.M., Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res. 21: 1531-1538, 2004.
20. Chinetti G., Lestavel S., Fruchart J.C., Clavey V. and Staels B., Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ. Res. 92: 212-217, 2003.
21. Israelian-Konaraki Z. and Reaven P.D., Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 103: 1-9, 2005.
22. Collins A.R., Pleiotropic vascular effects of PPARgamma ligands. Drug News Perspect. 16: 197-204, 2003.
23. Lee D.L., Webb R.C. and Jin L., Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44: 796-799, 2004.
24. Jaye M., LXR agonists for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 4: 1053-1058, 2003.
25. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H. and Mangelsdorf D.J., Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277: 18793-18800, 2002.
26. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L. and Mangelsdorf D.J., Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14: 2819-2830, 2000.
27. Mak P.A., Laffitte B.A., Desrumaux C., Joseph S.B., Curtiss L.K., Mangelsdorf D.J., Tontonoz P. and Edwards P.A., Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277: 31900-31908, 2002.
28. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N. Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willson T.M. and Tontonoz P., Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99: 7604-7609, 2002.
29. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J., Wang X., Lusis A.J., Tontonoz P. and Schulman I.G., Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA 99: 11896-11901, 2002.
30. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D. and Shan B., Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838, 2000.
31. Stocker R. and Keaney J.F. Jr, Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-478, 2004.
32. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., Vahabzadeh K., Hama S., Hough G., Kamranpour N., Berliner J.A., Lusis A.J. and Fogelman A.M., The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid. Res. 2004(45) 993-1007, 2004.
33. Madamanchi N.R., Vendrov A. and Runge M.S., Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25: 29-38, 2005.
34. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., Singh P., Anantharamaiah G.M., Chait A., Brunzell J., Geary R.L., Oram J.F. and Heinecke J.W., The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA 31(101) 13032-13037, 2004.
35. Chisolm G.M. and Steinberg D., The oxidative modification hypothesis of atherogenesis. An overview. Free Radic. Biol. Med. 28: 1815-1826, 2000.
36. Harrison D.G., Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 100: 2153-2157, 1997.
37. Guzik T.J., West N.E.J., Black E., McDonald D., Ratnatunga C., Pillai R. and Channon K.M., Vascular superoxide production by NAD(P)H oxidase. Associaton with endothelial dysfunction and clinical risk factors. Circ. Res. 86: e85-e90, 2000.
38. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K. and Harrison D.G., Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J. Clin. Invest. 97: 1916-1923, 1996.
39. Ross R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
40. Berliner J.A. and Heinecke J.W., The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20: 707-727, 1996.
41. Freeman B.A., White C.R., Gutierrez H., Paler-Martinez A., Tarpey M.M. and Rubbo H., Oxygen radical-nitric oxide reactions in vascular diseases. Adv. Pharmacol. 34: 45-69, 1995.
42. Alexander R.W., Atherosclerosis as disease of redox-sensitive genes. Trans. Am. Clin. Climatol. Assoc. 109: 129-145, 1998.
43. Ito H., Torii M. and Suzuki T., Decreased superoxide dismutase activity and increased superoxide anion production in cardiac hypertrophy of spontaneously hypertensive rats. Clin. Exp. Hypertens. 17: 803-816, 1995.
44. van Jaarsveld H., Kuyl J.M. and Alberts D.W., Exposure of rats to low concentration of cigarette smoke increases myocardial sensitivity to ischaemia/reperfusion. Basic Res. Cardiol. 87: 393-399, 1992.
45. Esposito L.A., Melov S., Panov A., Cottrell B.A. and Wallace D.C., Mitochondrial disease in mouse results in increased oxidative stress. Proc. Natl. Acad. Sci. USA 96: 4820-4825, 1999.
46. Wallace D.C., Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 256: 628-632, 1992.
47. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K. and Runge M.S., Mitochondrial integrity and function in atherogenesis. Circulation 106: 544-549, 2002.
48. Puddu P., Puddu G.M., Cravero E. and Muscari A., Mitochondrial dysfunction as an initiating event in atherogenesis - a plausible hypothesis. Cardiology 103: 137-141, 2005.
49. Ramachandran A., Levonen A.L., Brookes P.S., Ceaser E., Shiva S., Barone M.C. and Darley-Usmar V., Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radic. Biol. Med. 33: 1465-1474, 2002.
50. Chance B., Sies H. and Boveris A., Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59: 527-605, 1979.
51. Papa S. and Skulachev V.P., Reactive oxygen species, mitochondria, apoptosis and aging. Mol. Cell. Biochem. 174: 305-319, 1997.
52. Shackelford R.E., Kaufmann W.K. and Paules R.S., Oxidative stress and cell cycle checkpoint function. Free Radic. Biol. Med. 28: 1387-1404, 2000.
53. Ballinger S.W., Patterson C., Yan C.N., Doan R., Burow D.L., Young C.G., Yakes P.M., Van Houten B., Ballinger C.A., Freeman B.A. and Runge M.S., Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ. Res. 86: 960-966, 2000.
54. Yan L.J. and Sohal R.S., Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc. Natl. Acad. Sci. USA 95: 12896-12901, 1998.
55. MacMillan-Crow L.A., Crow J.P. and Thompson J.A., Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 37: 1613-1622, 1998.
56. Knight-Lozano C.A. Young C.G, Burow D.L, Hu Z.Y, Uyeminami D., Pinkerton K.E., Ischiropoulos H. and Ballinger S.W., Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation 105: 849-854, 2002.
57. Dart A.M. and Chin-Dusting J.P.F., Lipids and the endothelium. Cardiovasc. Res. 43: 308-322, 1999.
58. Lewis T.V., Dart A.M. and Chin-Dusting J.P.F., Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J. Am. Coll. Cardiol. 33: 805-812, 1999.
59. Parhami F., Fang Z.T., Fogelman A.M., Andalibi A., Territo M.C. and Berliner J.A., Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J. Clin. Invest. 92: 471-478, 1993.
60. Vora D.K., Fang Z.T., Liva S.M., Tyner T.R., Parhami F., Watson A.D., Drake T.A., Territo M.C. and Berliner J.A., Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ. Res. 80: 810-818, 1997.
61. Smalley D.M., Lin J.H., Curtis M.L., Kobari Y., Stemerman M.B. and Pritchard K.A. Jr., Native LDL increase endothelial cell adhesiveness by inducing intercellular adhesion molecule-1. Arterioscler. Thromb. Vasc. Biol. 16: 585-590, 1996.
62. Lin J.H., Zhu Y., Liao H.L., Kobari Y., Groszek L. and Stemerman M.B., Induction of vascular cell adhesion molecule-1 by low-density lipoprotein. Atherosclerosis 127: 185-194, 1996.
63. Allen S., Khan S., Al-Mohanna F., Batten P. and Yacoub M., Native low-density lipoprotein-induced calcium transient trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J. Clin. Invest. 101: 1064-1075, 1998.
64. Rajavashisth T.B., Andalibi A., Territo M.C., Berliner J.A., Navab M., Fogelman A.M. and Lusis A.J., Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344: 254-247, 1990.
65. Johnson-Tidey R.R., McGregor J.L., Taylor P.R. and Poston R.N., Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques.Coexpression with intercellular adhesion molecule-1. Am. J. Pathol. 144: 952-961, 1994.
66. Khan B.V., Harrison D.G., Olbrych M.T., Alexander R.W. and Medford R.M., Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc. Natl. Acad. Sci. USA 93: 9114-9119, 1996.
67. Sugiyama S., Kugiyama K., Ohgushi M., Fujimoto K. and Yasue H., Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ. Res. 74: 565-575, 1994.
68. Maier J.A., Barenghi L., Bradamante S. and Pagani F., Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem. Biophys. Res. Commun. 204: 673-677, 1994.
69. Myers D.E., Huang W.N. and Larkins R.G., Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification. Am. J. Physiol. 271: C1504-C1511, 1996.
70. Haug C., Schmid-Kotsas A., Zorn U., Schuett S., Gross H.J., Gruenert A. and Bachem M.G., Endothelin-1 synthesis and endothelin b receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. J. Mol. Cell Cardiol. 33: 1701-1712, 2001.
71. He Y., Kwan W.C. and Steinbrecher U.P., Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and pacrophages. Atherosclerosis 119: 107-118, 1996.
72. Lindner V., Lappi D.A., Baird A., Majack R.A. and Reidy M.A., Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res. 68: 106-113, 1991.
73. Stiko-Rahm A., Hultgardh-Nilsson A., Regnstrom J., Hamsten A. and Nilsson J., Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler. Thromb. 12: 1099-1109, 1992.
74. Kohno M., Yokokawa K., Yasunari K., Minami M., Kano H., Hanehira T. and Yoshikawa J., Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98: 353-359, 1998.
75. Kim J.G., Taylor W.R. and Parthasarathy S., Demonstration of the presence of lipid peroxide-modified proteins in human atherosclerotic lesions using a novel lipid peroxidemodified anti-peptide antibody. Atherosclerosis 143: 335-340, 1999.
76. Mertens A. and Holvoet P., Oxidized LDL and HDL. Antagonists in atherothrombosis. FASEB J. 15: 2073-2084, 2001.
77. Thorin E., Hamilton C.A., Dominiczak M.H. and Reid J.L., Chronic exposure of cultured bovine endothelial cells to oxidized LDL abolishes prostacyclin release. Arterioscler. Thromb. 14: 453-459, 1994.
78. Li L.X., Chen J.X., Liao D.F. and Yu L., Probucol inhibits oxidized-low density lipoprotein-induced adhesion of monocytes to endothelial cells by reducing P-selectin synthesis in vitro. Endothelium 6: 1-8, 1998.
79. Frei B. and Gaziano J.M., Content of antioxidants, preformed lipid hydroperoxides and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and-independent oxidation. J. Lipid Res. 34: 2135-2145, 1993.
80. Penn M.S., Vui M.Z., Winokur A.L., Bethea J., Hamilton T.A., DiCorleto P.E. and Chisolm G.M., Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. Blood 96: 30556-33063, 2000.
81. Ishii H., Kizaki K., Horie S. and Kazama M., Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes. J. Biol. Chem. 271: 8458-8465, 1996.
82. Kockx M.M., Apoptosis in the atherosclerotic plaque. Quantitative and qualitative aspects. Arterioscler. Thromb. Vasc. Biol. 18: 1519-1522, 1998.
83. Heermeier K., Leicht W., Palmetshofer A., Ullrich M., Wanner C. and Galle J., Oxidized LDL suppresses NF-kappa B and overcomes protection from apoptosis in activated endothelial cells. J. Am. Soc. Nephrol. 12: 456-463, 2001.
84. Metzler B., Hu Y., Dietrich H. and Xu Q., Increased expression and activation of stress-activated protein kinases/c-Jun NH (2)-terminal protein kinases in atherosclerotic lesions coincide with p53. Am. J. Pathol. 156: 1875-1886, 2000.
85. Carlos T.M. and Harlan J.M., Leukocyte-endothelial adhesion molecules. Blood 84: 2068-2101, 1994.
86. Frenette P. and Wagner D., Adhesion molecules. New Engl. J. Med. 334: 1526-1529, 1996.
87. Vora D.K., Fang Z.T., Liva S.M., Tyner T.R., Parhami F., Watson A.D., Drake T.A., Territo M.C. and Berliner J.A., Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ. Res. 80: 810-818, 1997.
88. Dong Z.M., Chapman S.M., Brown A.A., Frenette P.S., Hynes R.O. and Wagner D.D., The combined role of P-and E-selectins in atherosclerosis. J. Clin. Invest. 102: 145-152, 1998.
89. Frenette P.S. and Wagner D.D., Insights into selectin function from knockout mice. Thromb. Haemost. 78: 60-64, 1997.
90. Johnson R.C., Chapman S.M., Dong Z.M., Ordovas J.M., Mayadas T.N., Herz J., Hynes R.O., Schaefer E.J. and Wagner D.D., Absence of P-selectin delays fatty streak formation in mice. J. Clin. Invest. 99: 1037-1043, 1997.
91. Cybulsky M.I. and Gimbrone M.A. Jr., Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251: 788-791, 1991.
92. Li H., Cybulsky M.I., Gimbrone M.A. Jr and Libby P., An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler. Thromb. 1993(. 13) 197-204, 1991.
93. Iiyama K., Hajra L., Iiyama M., Li H., Di Chiara M., Medoff B.D. and Cybulsky M.I., Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ. Res. 85: 199-207, 1999.
94. Gurtner G.C., Davis V., Li H., McCoy M.J., Sharpe A. and Cybulsky M.I., Targeted disruption of the murine VCAM1 gene. Essential role of VCAM-1 in choriooallantoic fusion and placentation. Genes Dev. 9: 1-14, 1995.
95. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P. and Rollins B.J., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice. Mol. Cell. 2: 275-281, 1998.
96. Cook-Mills J.M., Johnson J.D., Deem T.L., Ochi A., Wang L. and Zheng Y., Calcium mobilization and Rac1 activation are required for VCAM-1 (vascular cell adhesion molecule-1) stimulation of NADPH oxidase activity. Biochem. J. 378: 539-547, 2004.
97. Eriksson E.E., Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr. Opin. Lipidol. 15: 553-558, 2004.
98. Witztum J.L. and Berliner J.A., Oxodized phospholipids and isoprostanes in atherosclerosis. Curr. Opin. Lipidol. 9: 441-448, 1998.
99. Gimbrone M.A. Jr., Nagel T. and Topper J.N., Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J. Clin. Invest. 100: S61-65, 1997.
100. Collins T., Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 68: 499-508, 1993.
101. Boring L., Gosling J., Cleary M. and Charo I.F., Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897, 1998.
102. Watson A.D., Leitinger N., Navab M., Faull K.F., Horkko S., Witztum J.L., Palinski W., Schwenke D., Salomon R.G., Sha W., Subbanagounder G., Fogelman A.M. and Berliner J.A., Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607, 1997.
103. Wheeler A.P. and Ridley A.J., Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. 301: 43-49, 2004.
104. Van Aelst L. and D'Souza-Schorey C., Rho GTPases and signaling networks. Genes Dev. 11: 2295-2322, 1997.
105. Scita G., Tenca P., Frittoli E., Tocchetti A., Innocenti M., Giardina G. and Di Fiore P.P., Signaling from Ras to Rac and beyond: not just a matter of GEFs. EMBO J. 19: 2393-2398, 2000.
106. Danesh F.R., Sadeghi M.M., Amro N., Philips C., Zeng L., Lin S., Sahai A. and Kanwar Y.S., 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc. Natl. Acad. Sci. USA 99: 8301-8305, 2002 (Epub 2002 Jun 04).
107. Eto M., Kozai T., Cosentino F., Joch H. and Luscher T.F., Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105: 1756-1759, 2002.
108. Endres M. and Laufs U., Effects of statins on endothelium and signaling mechanisms. Stroke 35: 2708-2711, 2004.
109. Ruiz-Velasco N. and Dominguez A., Vega.Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem. Pharmacol. 67: 303-313, 2004.
110. Bhattacharya M., Babwah A.V. and Ferguson S.S., Small GTP-binding protein-coupled receptors. Biochem. Soc. Trans. 32: 1040-1044, 2004.
111. Laufs U. and Liao J.K., Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273: 24266-24271, 1998.
112. Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D.S., Yang S.X., Simoncini T., Yamada M., Rabkin E., Allen P.G., Huang P.L., Bohm M., Schoen F.J., Moskowitz M.A. and Liao J.K., Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106: 15-24, 2000.
113. Goldstein J.L. and Brown M.S., Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
114. Park H.J., Kong D., Iruela-Arispe L., Begley U., Tang D. and Galper J.B., 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91: 143-150, 2002.
115. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., Bohm M. and Nickenig G., Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. 59: 646-654, 2001.
116. Wagner A.H., Kohler T., Ruckschloss U., Just I. and Hecker M., Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20: 61-69, 2000.
117. Gorlach A., Brandes R.P., Nguyen K., Amidi M., Dehghani F. and Busse R., A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ. Res. 87: 26-32, 2000.
118. Ishibashi T., Nagata K., Ohkawara H., Sakamoto T., Yokoyama K., Shindo J., Sugimoto K., Sakurada S., Takuwa Y., Teramoto T. and Maruyama Y., Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim. Biophys. Acta. 1590: 123-130, 2002.
119. Marrero M.B., Venema V.J., Ju H., He H., Liang H., Caldwell R.B. and Venema R.C., Endothelial nitric oxide synthase interactions with G-protein-coupled receptors. Biochem. J. 343: 335-340, 1999.
120. Tsutsui M., Shimokawa H., Tanaka S., Kuwaoka I., Hase K., Nogami N., Nakanishi K. and Okamatsu S., Endothelial Gi protein in human coronary arteries. Eur. Heart J. 15: 1261-1266, 1994.
121. Yang C.M., Chien C.S., Hsiao L.D., Pan S.L., Wang C.C., Chiu C.T. and Lin C.C., Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br. J. Pharmacol. 132: 1531-1541, 2001.
122. Yang C.M., Chiu C.T., Wang C.C., Chien C.S., Hsiao L.D., Lin C.C., Tu M.T. and Pan S.L., Activation of mitogen-activated protein kinase by oxidized low-density lipoprotein in canine cultured vascular smooth muscle cells. Cell Signal. 12: 205-214, 2000.
123. Zhao D., Letterman J. and Schreiber B.M., β-Migrating very low density lipoprotein (βVLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor. J. Biol. Chem. 276: 30579-30588, 2001.
124. Uittenbogaard A. and Smart E.J., Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J. Biol. Chem. 275: 255595-255599, 2000.
125. Everson W.V. and Smart E.J., Influence of caveolin, cholesterol and lipoproteins on nitric oxide synthase. Implications for vascular disease. Trends Cardiovasc. Med. 11: 246-250, 2001.
126. Uittenbogaard A., Ying Y. and Smart E.J., Characterization of a cytosolic heat-shock protein-caveolin chaperone complex. Involvement in cholesterol trafficking. J. Biol. Chem. 273: 6525-6532, 1998.
127. Stein O. and Stein Y., Atheroprotective mechanisms of HDL. Atherosclerosis 144: 285-303, 1999.
128. Von Eckardstein A. and Assmann G., Prevention of coronary heart disease by raising of high density lipoprotein cholesterol? Curr. Opin. Lipidol. 11: 627-637, 2000.
129. Toikka J.O., Ahotupa M., Viikari J.S., Niinikoski H., Taskinen M., Irjala K., Hartiala J.J. and Raitakari O.T., Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 147: 133-138, 1999.
130. Krause B.R. and Auerbach B.J., Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 2: 375-381, 2001.
131. von Eckardstein A., Nofer J.R. and Assmann G., High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21: 13-27, 2001.
132. Fazio S., Increased atherogenesis in mice reconstituted with apolipoprotein E null macrophages. Proc. Natl. Acad. Sci. USA 94: 4647-4652, 1997.
133. Ohgami N., Nagai R., Miyazaki A., Ikemoto M., Arai H., Horiuchi S. and Nakayama H., Scavenger receptor class B type-I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J. Biol. Chem. 276: 13348-13355, 2001.
134. Wade D.P. and Owen J.S., Regulation of the cholesterol efflux gene. ABCA1. Lancet 357: 161-163, 2001.
135. Wang N., Silver D.L., Thiele C. and Tall A.R., ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J. Biol. Chem. 276: 23742-23747, 2001.
136. Frank P.G., Galbiati F., Volonte D., Razani B., Cohen D.E., Marcel Y.L. and Lisanti M.P., Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins. Am. J. Physiol. Cell Physiol. 280: C1204-C1214, 2001.
137. Oliver W.R. Jr, Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C. and Willson T.M., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98: 5306-5311, 2001.
138. Fazio S. and Linton M.F., The inflamed plaque. Cytokine production and cellular cholesterol balance in the vessel wall. Am. J. Cardiol. 88: 12E-15E, 2001.
139. Yamashita S., Hirano K., Sakai N. and Matsuzawa Y., Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim. Biophys. Acta 1529: 257-275, 2000.
140. Krieger M., Charting the fate of the good cholesterol. Identification and characterization of the high density lipoprotein receptor SR-BI. Ann. Rev. Biochem. 68: 523-558, 1999.
141. Trigatti B., Rigotti A. and Krieger M., The role of high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin. Lipidol. 11: 123-132, 2000.
142. Curtiss L.K. and Boisvert W.A., Apolipoprotein E and atherosclerosis. Curr. Opin. Lipidol. 11: 243-251, 2000.
143. Tall A.R., Jiang X.C., Luo Y. and Silver D., George Lyman Duff Memorial Lecture. Lipid transfer proteins, HDL metabolism and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20: 1185-1188, 2000.
144. Cohen J., Vega G.L. and Grundy S.M., Hepatic lipase. New insights from genetic and metabolic studies. Curr. Opin. Lipidol. 10: 259-268, 1999.
145. Thuren T., Hepatic lipase and HDL metabolism. Curr. Opin. Lipidol. 11: 277-284, 2000.
146. Rader D. and Jaye M., Endothelial lipase. A new member of the triglyceride lipase gene family. Curr. Opin. Lipidol. 11: 141-148, 2000.
147. VonEckardstein A., Huang Y. and Assmann G., Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr. Opin. Lipidol. 5: 404-416, 1994.
148. Barrans A., Jaspard B., Barbaras R., Chap H., Perret B. and Collet X., Pre-β HDL. Structure and metabolism. Biochim. Biophys. Acta 1300: 73-85, 1996.
149. Fielding C. and Fielding P.E., Molecular physiology of reverse cholesterol transport. J. Lipid. Res. 36: 211-228, 1995.
150. Moestrup S.K. and Kozyraki R., Cubilin, a high density lipoprotein receptor. Curr. Opin. Lipidol. 11: 133-140, 2000.
151. Kozyraki R., Fyfe J., Kristiansen M., Gerdes C., Jacobsen C., Cui S.Y., Christensen E.I., Aminoff M., de la Chapelle A., Krahe R. et al., The intrinsic factor-vitamin B-12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat. Med. 5: 656-661, 1999.
152. Hammad S.M., Steffansson S., Twal W.O., Drake C.J., Fleming P., Remaley A., Brewer H.B. Jr and Argraves W.S., Cubilin, the endocytic receptor for intrinsic factor-vitamin B (12) complex, mediates high-density lipoprotein holoparticle endocytosis. Proc. Natl. Acad. Sci. USA 96: 10158-10163, 1999.
153. Dhaliwal B.S. and Steinbrecher U.P., Cholesterol delivered to macrophages by oxidized low density lipoprotein is sequestered in lysosomes and fails to efflux normally. J. Lipid. Res. 41: 1658-1665, 2000.
154. Aviram M. and Rosenblat M., Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37: 1304-1316, 2004.
155. Becker A.E., de Boer O.J. and van der Wal A.C., The role of inflammation and infection in coronary artery disease. Ann. Rev. Med. 52: 289-297, 2001.
156. Vander Wal A.C., Piek J.J., de Boer O.J., Koch K.T., Teeling P., van der Loos C.M. and Becker A.E., Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 80: 14-18, 1998.
157. Libby P., Changing concepts of atherogenesis. J. Int. Med. 247: 349-358, 2000.
158. Libby P., Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850, 1995.
159. Herman M.P., Sukhova G.K., Kisiel W., Foster D., Kehry M.R., Libby P. and Schonbeck U., Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest. 107: 1117-1126, 2001.
160. Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S. and Libby P., Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40, induction of collagenase, stromelysin and tissue factor. Circulation 96: 396-399, 1997.
161. Schonbeck U., Mach F., Sukhova G.K., Herman M., Graber P., Kehry M.R. and Libby P., CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am. J. Pathol. 156: 7-14, 2000.
162. Marx N., Mackman N., Schonbeck U., Yilmaz N., Hombach V.V., Libby P. and Plutzky J., PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103: 213-219, 2001.
163. Yusuf S., Dagenais G., Pogue J., Bosch J. and Sleight P., Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342: 154-160, 2000.
164. Heart Protection Study Collaborative Group., MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 23-33, 2002.
165. Ricciarelli R., Zingg J.M. and Azzi A., Vitamin E. Protective role of a Janus molecule. FASEB J. 15: 2314-2325, 2001.
166. Heinecke J.W., Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler. Thromb. Vasc. Biol. 21: 1261-1264, 2001.
167. Keaney J.F. Jr., Atherosclerosis. From lesion formation to plaque activation and endothelial dysfunction. Mol. Aspects. Med. 21: 99-166, 2000.
168. Libby P., Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104: 365-372, 2001.
169. Jessup W., Kritharides L. and Stocker R., Lipid oxidation in atherogenesis: an overview. Biochem. Soc. Trans. 32: 134-138, 2004.
170. Stocker R. and Keaney J.F. Jr., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84: 1381-1478, 2004.
171. Vaughan C.J., Gotto A.M. and Basson C.T., The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35: 1-10, 2000.
172. Puddu P., Puddu G.M. and Muscari A., Current thinking in statin therapy. Acta Cardiol. 56: 225-231, 2001.
173. Puddu P., Puddu G.M. and Muscari A., HMG-CoA reductase inhibitors. Is the endothelium the main target?. Cardiology 95: 9-13, 2001.
174. Ambrosi P., Villani P., Habib G. and Bouvenot G., The statins: new properties. Therapie 58: 15-21, 2003.
175. Parissis J., Korovesis S., Kalivas P., Giagitzoglou E. and Katritsis D., Short-term atorvastatin therapy reduces monocyte-related inflammatory markers in the serum of hypercholesterolaemic patients. Eur. Heart J. 21: 154, 2000.
176. Chase A.J. and Newby A.C., Cerivastatin inhibits metalloproteinase production by human vascular smooth muscle cells in response to inflammatory stimuli, a possible mechanism for plaque stabillisation. Eur. Heart J. 21: 152, 2000.
177. Sinkiewicz W., Hoffman A., Blazejewski J., Bujak R., Budzynski J., Zbikowska M. and Palgan K., The serum immunoglobulin IgE, interleukin-4 and soluble form receptor CD23 dynamic changes in patients with hypercholesterolaemia II B treated with pravastatin. Eur. Heart J. 21: 155, 2000.
178. Paul A., Calleja L., Camps J., Osada J., Vilella E., Ferré N., Mayayo E. and Joven J., The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 68: 457-465, 2000.
179. Fuster V., Dyken M.L., Vokonas P.S. and Hennekens C., Aspirin as a therapeutic agent in cardiovascular disease. Circulation 87: 659-675, 1993.
180. Jukema J.W., Matching treatment to the genetic basis of (lipid) disorder in patients with coronary artery disease. Heart 82: 126-127, 1999.